Compare HOV & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | ARVN |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | 1891 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.9M | 658.2M |
| IPO Year | N/A | 2018 |
| Metric | HOV | ARVN |
|---|---|---|
| Price | $100.33 | $10.76 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $97.00 | $15.05 |
| AVG Volume (30 Days) | 91.0K | ★ 651.5K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $85.69 | $5.90 |
| 52 Week High | $162.06 | $14.22 |
| Indicator | HOV | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 49.58 |
| Support Level | $100.24 | $9.02 |
| Resistance Level | $113.60 | $12.43 |
| Average True Range (ATR) | 5.82 | 0.51 |
| MACD | -1.20 | 0.04 |
| Stochastic Oscillator | 4.68 | 61.68 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.